References and important publications

Barbui, C., Nose, M., Bindman, J., Schene, A., Becker, T., Mazzi, M., Kikkert, M., Camara, J., Born, A., Tansella, M. Sex Differences in the Subjective Tolerability of Antipsychotic Drugs Journal of Clinical Psychopharmacology, 2015; 25(6), 521-526

Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F., Thibaut, F., Moller, H.J., WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. The World Journal of Biological Psychiatry, 2013; 14: 2-44

NICE Guidelines: Psychosis and schizophrenia in adults: prevention and management. Evidence-based recommendations on the prevention and management of psychosis and schizophrenia in adults. Clinical Guideline 178. Published 2014.

Joukamaa, M., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., Lehtinen, V. Schizophrenia, neuroleptic medication and mortality. The British Journal of Psychiatry, 2006;188(2), 122-127.

Moncrieff, J., Cohen, D. How do psychiatric drugs works? BMJ, 2009;338:b1963

Osborn, D.P.J., Nazareth, I., King, M.B. Physical activity, dietary habits and Coronary Heart Disease risk factor knowledge amongst people with severe mental illness. A cross sectional comparative study in primary care. Soc Psychiatry Psychiatr Epidemiol. 2007;42: 787-793.

Ray, W.A., Chung, C.P., Murray, K.T., Hall, K., Stein, C.M. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. The New England Journal of Medicine, 2009;360:3

Wiersma, D., Wanderling, J., Dragomirecka, E., Ganev, K., Harrison, G., An Der Heiden, W.,...Walsh, D. (2000). Social disability in schizophrenia: Its development and prediction over 15 years in incidence cohorts in six European centres. Psychological Medicine, 30(5), 1155-1167.

Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment StrategyLong-term Follow-up of a 2-Year Randomized Clinical Trial. JAMA Psychiatry. 2013;70(9):913-920. doi:10.1001/jamapsychiatry.2013.19